Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
NEW YORK - SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), a biotechnology company with a market capitalization of $216.5 million that has seen its stock surge over 106% in the past six months, announced Monday the appointment of Linghua Wang, MD, PhD, to its Scientific Advisory Board (SAB). According to InvestingPro data, the company maintains strong financial health with a current ratio of 4.64, indicating robust short-term liquidity.
Dr. Wang, a tenured Associate Professor in the Department of Genomic Medicine at MD Anderson Cancer Center, joins the company’s advisory team shortly after the recent additions of Philip C. Amrein, MD, and Alex Kentsis, MD, PhD. The company’s strategic appointments come as it trades near its 52-week high of $2.27, with InvestingPro analysis revealing 12 additional key insights about the company’s performance and prospects.
Wang leads the Computational Biology Laboratory at MD Anderson and holds multiple appointments, including Associate Member of The James P. Allison Institute. Her research focuses on tumor ecosystems, cellular and molecular heterogeneity, and interactions between cancer cells and the tumor microenvironment.
"Her decades of experience in cancer immunogenomics and computational biology are directly aligned with our focus on translational research, artificial intelligence utilization around genomics, proteomics as well as transcriptomics, and precision medicine," said Dragan Cicic, MD, Senior Vice President and Chief Development Officer of SELLAS.
Wang’s laboratory utilizes single-cell and spatial omics, molecular imaging, and advanced bioinformatics approaches in cancer research. She has published over 100 articles in scientific journals and holds multiple NIH/NCI funded grants.
SELLAS is developing two main product candidates: GPS, which targets the WT1 protein present in various tumor types, and SLS009 (tambiciclib), a CDK9 inhibitor being developed for acute myeloid leukemia.
The company stated it expects key clinical milestones for both of its assets later this year, according to the press release statement. Analyst expectations remain optimistic, with price targets ranging from $4.00 to $7.50 per share. For deeper insights into SELLAS’s financial health and growth prospects, investors can access comprehensive analysis through InvestingPro’s extensive metrics and expert recommendations.
In other recent news, SELLAS Life Sciences Group, Inc. has announced its upcoming inclusion in the Russell 3000 and Russell 2000 Indexes, effective after the market close on June 27. This inclusion marks a significant milestone for the company, indicating its standing among the largest publicly traded U.S. companies. SELLAS has also expanded its Scientific Advisory Board by adding two renowned oncology specialists, Philip C. Amrein, MD, and Alex Kentsis, MD, PhD, to support its clinical programs. The company’s lead product candidates, GPS and SLS009, are advancing through critical phases, with SLS009 showing promising preclinical data for colorectal cancer and acute myeloid leukemia (AML).
SELLAS has initiated a Phase 2 trial of SLS009 for pediatric patients with relapsed/refractory AML, highlighting its focus on unmet medical needs in hematologic conditions. The trial aims to assess the safety and efficacy of SLS009 in combination with other drugs. Additionally, the company has reported preclinical data suggesting SLS009’s potential as a treatment option for AML with TP53 mutations, showing significant reduction in leukemia cells. These developments underscore SELLAS’s ongoing efforts in oncology drug development, with a focus on therapies for various cancer indications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.